Table 1.

Association between bevacizumab and the occurrence of hypertension in FDA Adverse Event Reporting System.

Group	Hypertension without bevacizumab (%)	Hypertension with bevacizumab (%)	ROR	95%CI	p‐value
Total	83559/3695466 (2.26)	1520/28288 (5.37)	2.45	2.33‐2.59	<0.001
Stratified by gender
Male	28076/1274753 (2.2)	414/11466 (3.61)	1.66	1.51‐1.84	<0.001
Female	51603/2090097 (2.47)	776/13658 (5.68)	2.38	2.21‐2.56	< 0.001
Stratified by age (y)
<40	8342/527869 (1.58)	60/1232 (4.87)	3.19	2.46‐4.14	<0.001
40~4	7758/321558 (2.41)	104/1998 (5.21)	2.22	1.82‐2.71	<0.001
50~59	13054/470547 (2.77)	214/4062 (5.27)	1.95	1.7‐2.24	<0.001
60~69	14250/472096 (3.02)	299/5476 (5.46)	1.86	1.65‐2.09	<0.001
70~100	15478/529240 (2.92)	248/4663 (5.32)	1.86	1.64‐2.12	<0.001